Recent Company News

• 09:41 PM ET Apr 14, 2026
  

  StreetAccount Summary - Trading higher/lower: Australia & New Zealand midday

• 08:00 PM ET Apr 29, 2026
  

  Mesoblast reports Q3 net cash from / (used in) operating activities ($4.1M) - Appendix 4C (A$2.22, 0.00)

• 07:53 PM ET Apr 28, 2026
  

  Mesoblast reports Phase 3 clinical trial evaluating rexlemestrocel-L for treatment of CLBP achieves patient recruitment target (A$2.15, 0.00)

• 12:16 AM ET Apr 15, 2026
  

  StreetAccount Scorecard - Australian ASX200 short interest as at 8-Apr

• 07:36 PM ET Apr 14, 2026
  

  Mesoblast acquires global license to chimeric antigen receptor technology platform; consideration 1.3M shares (A$2.01, 0.00)

• 08:02 AM ET Apr 13, 2026
  

  Insider transaction: Mesoblast holder Gregory George discloses purchase of 7.9M shares - Form 4 (A$2.02, 0.00)

• 11:33 AM ET Apr 08, 2026
  

  Transcript Intelligence: Mesoblast R&D Day

• 08:28 AM ET Apr 08, 2026
  

  StreetAccount Sector Summary - Healthcare Pre-Market